ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 121427" data-attributes="member: 13851"><p><strong>Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study</strong></p><p><em>Tatiane Fernandes, MD, Adriana O. Pedro, MD, PhD, Luiz F. Baccaro, MD, PhD,</em></p><p><em>and Lucia H. Costa-Paiva, MD, PhD</em></p><p></p><p></p><p><strong>CONCLUSIONS</strong></p><p><strong></strong></p><p><strong><em>In conclusion, these data show that 12 weeks of treatment with topical testosterone or topical estrogen in postmenopausal women with symptoms of vaginal atrophy demonstrated laboratory and endometrial safety when compared with placebo. The high prevalence of symptomatology in menopausal urogenital atrophy reinforces the need to explore alternative treatments to estrogen therapy to improve the quality of life of these women.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 121427, member: 13851"] [B]Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study[/B] [I]Tatiane Fernandes, MD, Adriana O. Pedro, MD, PhD, Luiz F. Baccaro, MD, PhD, and Lucia H. Costa-Paiva, MD, PhD[/I] [B]CONCLUSIONS [I]In conclusion, these data show that 12 weeks of treatment with topical testosterone or topical estrogen in postmenopausal women with symptoms of vaginal atrophy demonstrated laboratory and endometrial safety when compared with placebo. The high prevalence of symptomatology in menopausal urogenital atrophy reinforces the need to explore alternative treatments to estrogen therapy to improve the quality of life of these women.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top